AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.

Background: Bevacizumab (Avastin®), a recombinant humanized monoclonal antibody, in combination with platinum-doublet chemotherapy has become a routine treatment for advanced non-small-cell lung cancer (NSCLC). The post-authorization, non-interventional study 'AVAiLABLE' assessed the effectiveness and safety of bevacizumab combined with chemotherapy as first-line treatment.

Methods: Nine hundred and eighty-seven adult patients (mean age 61.